Synapse - Department of Medicine

Results (39721)

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214

Meeting Abstract

Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development

Meeting Abstract

Gaffney, C.; Jiang, S.; de Jesus, M. R.; Chu, C. E.; Benfante, N.; Bajorin, D. F.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Bochner, B. H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial

Meeting Abstract

Burotto, M.; Powles, T.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Characterizing the immune phenotype of FGFR3 mutated upper tract urothelial carcinoma (UTUC) using single-cell (sc)RNA-sequencing (seq)

Meeting Abstract

Katims, A. B.; Kuo, F.; Reisz, P.; Tracey, A.; Thomas, J.; Yip, W.; Merghoub, T.; Bochner, B. H.; Pietzak, E. J.; Solit, D. B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC)

Meeting Abstract

Katims, A. B.; Lenis, A. T.; Shah, R. H.; Chu, C. E.; Ratna, N.; Regazzi, A. M.; Pietzak, E. J.; Aggen, D. H.; Funt, S. A.; Teo, M. Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study

Meeting Abstract

Milowsky, M. I.; O'Donnell, P. H.; Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Moon, H. H.; Friedlander, T. W.; Mar, N.; McKay, R. R.; Srinivas, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K

Meeting Abstract

O'Donnell, P. H.; Rosenberg, J. E.; Hoimes, C. J.; Petrylak, D. P.; Milowsky, M. I.; McKay, R. R.; Srinivas, S.; Friedlander, T. W.; Ramamurthy, C.; Bilen, M. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer

Meeting Abstract

Aggen, D. H.; Hong, D. S.; Clarke, J. M.; Asch, A. S.; Calvo, E.; Zugazagoitia, J.; Butler, M. O.; Moreno, V.; Cervantes, A.; Van Tine, B. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC)

Meeting Abstract

Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer

Meeting Abstract

Barnett, E.; Woo, S.; Perk, T. G.; Munian-Govindan, R.; Lokre, O.; Gajar, R. N.; Erazo, T.; Carbone, E.; Morris, M. J.; Vargas, H. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save